Monitor for any equity raise, reverse stock split, or other capital restructuring that MTNB may pursue to regain compliance before the October 2027 deadline. Failure to comply will trigger delisting proceedings, which would severely impair liquidity and likely lead to a near-total loss for common shareholders. The .BC indicator signals ongoing non-compliance to the market.
Price Chart
Executive Summary
Matinas BioPharma received a third NYSE American non-compliance notice, this time for failing Section 1003(a)(i) requiring $2.0M in stockholders' equity (reported $1.8M as of June 30, 2026). The company already had two prior non-compliance notices for higher equity thresholds and is operating under a compliance plan with a deadline of October 2, 2027. While trading continues with a .BC indicator, the cumulative equity deficiency and $3M market cap signal severe financial distress and elevated delisting risk.
Key Facts
- Received NYSE American non-compliance notice under Section 1003(a)(i) on August 31, 2026
- Stockholders' equity of $1.8M as of June 30, 2026, below the $2.0M minimum
- Company has reported losses in five consecutive fiscal years
- Already non-compliant with Sections 1003(a)(ii) ($4M equity) and 1003(a)(iii) ($6M equity) from prior notices
- Compliance plan accepted by NYSE American with plan period through October 2, 2027
- Common stock continues trading on NYSE American under MTNB with .BC indicator
- Market capitalization approximately $3M with minimal institutional ownership
Financial Impact
Stockholders' equity deficit of $0.2M against $2.0M minimum; cumulative non-compliance with three equity standards; delisting risk if not compliant by October 2, 2027
Risk Factors
- Delisting from NYSE American if compliance not achieved by October 2, 2027
- Inability to raise sufficient capital to meet equity standards given $3M market cap
- Going-concern risk as losses continue with no approved products or revenue
- Potential reverse stock split or dilutive financing to boost equity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-041577 |
| Exhibit: ex99-1.htm | 0001493152-26-041577 |
| Document: 0001493152-26-041577-index-headers.html | 0001493152-26-041577 |
| Document: 0001493152-26-041577-index.html | 0001493152-26-041577 |
| Document: 0001493152-26-041577.txt | 0001493152-26-041577 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 29d ago | 8-K | $2.53 $1.66 | ▼ −34.39% | ▼ −34.36% | $1.83 (−27.67%) |
Sep 16, 2026 5w ago | 8-K | $0.1630 $0.1613 | ▼ −1.02% | ▼ −2.23% | $1.83 (+1022.70%) |
Sep 4, 2026 7w ago | 8-K | $0.1820 $3.01 | ▼ −1553.85% | ▼ −1552.13% | $1.83 (−905.49%) |
Aug 25, 2026 9w ago | 425 | $0.1973 $0.1750 | ▲ +11.30% | ▲ +12.28% | $1.83 (−827.52%) |
Jul 30, 2026 12w ago | 425 | $0.3174 $0.2000 | ▲ +36.99% | ▲ +40.95% | $1.83 (−476.56%) |
Jul 24, 2026 13w ago | 8-K | $0.3320 $0.1965 | ▲ +40.81% | ▲ +44.11% | $1.83 (−451.20%) |
Jul 13, 2026 15w ago | 425 | $0.4800 $0.2690 | ▲ +43.96% | ▲ +47.14% | $1.83 (−281.25%) |
Jul 13, 2026 15w ago | 8-K | $0.4800 $0.2690 | ▲ +43.96% | ▲ +47.14% | $1.83 (−281.25%) |
Jun 26, 2026 17w ago | 8-K | $0.6640 $0.2414 | ▲ +63.64% | ▲ +63.37% | $1.83 (−175.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers